Abstract
Mesenchymal stem cells are immunoregulation cells. IL-22 plays an important role in the pathogenesis of immune thrombocytopenia. However, the effects of mesenchymal stem cells on IL-22 production in patients with immune thrombocytopenia remain unclear. Flow cytometry analyzed immunophenotypes of mesenchymal stem cells; differentiation of mesenchymal stem cells was observed by oil red O and Alizarin red S staining; cell proliferation suppression was measured with MTS; IL-22 levels of cell-free supernatants were determined by ELISA. Mesenchymal stem cells inhibited the proliferation of activated CD4+T cells; moreover, mesenchymal stem cells immunosuppressed IL-22 by soluble cellular factors but not PGE2. These results suggest that mesenchymal stem cells may be a therapeutic strategy for patients with immune thrombocytopenia.
Highlights
Mesenchymal stem cells (MSCs) are multipotent cells and are able to differentiate into mature mesenchymal cells such as osteoblasts, adipocytes, and chondroblasts [1]
We have successfully demonstrated a previously uncharacterized fact that umbilical cord (UC)-MSCs possessed strong immunosuppressive capacity on IL-22 in patients with
Immunoregulation is one of the biological characteristics of MSCs; they can modulate the function of different immune cells such as T cells, B cells, neutrophils, natural killer (NK)
Summary
Mesenchymal stem cells (MSCs) are multipotent cells and are able to differentiate into mature mesenchymal cells such as osteoblasts, adipocytes, and chondroblasts [1]. . UC-MSCs are a more promising source [8]. Due to their stronger immunoregulation, MSCs have been widely applied for treatment of all kinds of diseases, for example, graftversus-host disease (GVHD) [9], experimental autoimmune encephalomyelitis (EAE) [10], Crohn’s disease (CD) [11], and rheumatoid arthritis (RA) [12]. It is known that T cells abnormalities play an important role in the pathogenesis of ITP. Many studies found that the concentration of IL-22 produced by T cell subsets increased significantly in ITP patients [16,17,18]. Our data suggest that UC-MSCs inhibited the proliferation of CD4+ T cells and immunosuppressed the production of IL-22 in ITP patients through soluble cellular factors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
